Table 1.
Demographic and clinical characteristics of participants in the CKD-MIT by CKD stage.
| CKD stage 3A (eGFR 45–59 mL/min/1.73 m2), n/N=49/141 | CKD Stage 3B (eGFR 30–44 mL/min/1.73 m2), n/N=52/141 | CKD stage 4/5 (eGFR 15–29 mL/min/1.73 m2), n/N=40/141 | Total combined in CKD-MIT (eGFR 15–59 mL/min/1.73 m2), N=141 | |||||
|---|---|---|---|---|---|---|---|---|
| Age (M±SD) | 68±11 | 72±9 | 67±13 | 69±11 | ||||
| n | % | N | % | n | % | n | % | |
| Sex | ||||||||
| Male | 28 | 57 | 23 | 44 | 23 | 56 | 74 | 52 |
| Female | 21 | 43 | 29 | 56 | 17 | 43 | 67 | 48 |
| Race | ||||||||
| White | 46 | 94 | 43 | 83 | 30 | 75 | 119 | 84 |
| Non-white | 3 | 6 | 9 | 17 | 10 | 25 | 22 | 16 |
| Ethnicity | ||||||||
| Hispanic | 0 | 0 | 3 | 6 | 0 | 0 | 3 | 2 |
| Non-Hispanic | 49 | 100 | 49 | 94 | 40 | 100 | 138 | 98 |
| Diabetes | 22 | 45 | 31 | 60 | 26 | 65 | 79 | 56 |
| Hypertension | 43 | 88 | 43 | 83 | 31 | 78 | 117 | 83 |
| M | SD | M | SD | M | SD | M | SD | |
| Prescription medications | 8.2 | 3.8 | 8.8 | 3.4 | 8.9 | 2.8 | 8.6 | 3.4 |
| OTC/herbal medications | 3.8 | 3.6 | 4.1 | 3.2 | 4.0 | 4.1 | 4.0 | 3.6 |
| Total medications | 12.0 | 5.5 | 12.9 | 4.5 | 12.9 | 5.2 | 12.6 | 5.1 |
| Total MRCI score | 22.8 | 12.6 | 23.9 | 9.8 | 25.1 | 9.5 | 23.9 | 10.7 |
CKD: chronic kidney disease; CKD-MIT: CKD-Medication Intervention Trial; eGFR: estimated glomerular filtration rate; M: mean; MRCI: medication regimen complexity index; OTC: over-the-counter; SD: standard deviation.